Therapeutic application of GPR119 ligands in metabolic disorders

E-ISSN： 1463-1326|20|2|257-269

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.2, 2018-02, pp. : 257-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GPR40: A therapeutic target for mediating insulin secretion (Review)

International Journal of Molecular Medicine, Vol. 30, Iss. 6, 2012-01 ,pp. : 1261-1266

Spandidos Publications

Access to resources Recommend Favorite

Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders)

Recent Patents on CNS Drug Discovery, Vol. 10, Iss. 2, 2015-08 ,pp. : 75-75

Bentham Science Publishers

Access to resources Recommend Favorite

Characterizing pharmacological ligands to study the long‐chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 13, 2015-07 ,pp. : 3254-3265

John Wiley & Sons Inc

Access to resources Recommend Favorite

Occurrence of tendon pathologies in metabolic disorders

By Abate Michele

British Journal of Rheumatology , Vol. 52, Iss. 4, 2013-04 ,pp. : 599-608

Oxford University Press

Access to resources Recommend Favorite

Pycnogenol® in Metabolic Syndrome and Related Disorders

PHYTOTHERAPY RESEARCH, Vol. 29, Iss. 7, 2015-07 ,pp. : 949-968

John Wiley & Sons Inc

Access to resources Recommend Favorite